Skip to main content

Table 1 Patients’ demographic and clinical characteristics

From: Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study

Variable Patients: n (%)a
Gender
 Male 274 (49)
 Female 281 (51)
Age
  ≤ 30 120 (21.6)
 31–40 94 (16.9)
 41–50 122 (22)
  > 50 219 (39.5)
Overall prescribed drugsb
  ≤ 5 111 (20)
 6–7 114 (20.5)
 8–9 131 (23.6)
  ≥ 10 199 (35.9)
Diagnoses
 Breast cancer 86 (15.5)
 Non hodgkin lymphoma 84 (15.1)
 Gastrointestinal cancer 71 (12.8)
 Gynecologic cancer 33 (5.9)
 Acute lymphoblastic leukemia 29 (5.2)
 Genitourinary cancer 23 (4.1)
 Hodgkin lymphoma 17 (3.1)
 Chronic lymphocytic leukemia 15 (2.7)
 Musculoskeletal cancer 14 (2.5)
 Acute mylogenous leukemia 11 (2)
 Ovarian cancer 11 (2)
 Colorectal carcinoma 11 (2)
 Lung cancer 10 (1.8)
 Head and neck cancer 8 (1.4)
Comorbidities
 Diabetes mellitus 27 (4.9)
 Hypertension 23 (4.1)
 Hepatitis B 3 (0.5)
 Hepatitis C 3 (0.5)
  1. aPercentage calculated in total number of patients i.e., 555
  2. bOverall prescribed medications mean QT prolonging medications as well as other medications